PE-22-28
Mini-analog of spadin with antidepressant-like effect in mice; in people, unknown.
Updated:
Affiliate link to this product’s page on Peptira. We may earn a commission at no extra cost to you. Code KAREL. Disclosure
Quick summary
PE-22-28 is a heptapeptide derived from spadin, a natural peptide that blocks the TREK-1 (KCNK2) potassium channel. In cells and mice, it shows potent TREK-1 inhibition and antidepressant-like behaviors with neurogenesis. Zero human clinicals.
Studied for
How it works
TREK-1 inhibition → increased excitability in circuits involved in mood (model). PE-22-28 was reported to be more potent/stable than spadin in the 2017 Frontiers paper.
What the research says
Key paper: PubMed 28955242 / PMC5601071. Remainder: TREK-1/spadin literature. No ClinicalTrials for PE-22-28 as an established human therapeutic.
Evidence level
D — preclinical
What's most reported
- Mice: less immobility in forced-swim, signs of neurogenesis
- Forums: mood — anecdotal
Common side effects
Unknown in humans.
Combines / does not combine
Do not empirically combine with antidepressants without supervision: theoretical risk of unstudied central interactions.
Frequently asked questions
No.
No; distinct TREK-1 mechanism from the Russian ACTH analogs.
Keep exploring
Keep learning
Related peptides
Educational content. Not medical advice or usage guidance. Research products are not approved medications unless otherwise indicated.